品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com

BioXcell/InVivoMAb anti-rat IgG1/DISCOUNTED ACADEMIC OR NON PROFIT: 100MG/BE0250-A100mg

价格
¥65000.00
货号:BE0250-A100mg
浏览量:73
品牌:BioXcell
服务
全国联保
正品保证
正规发票
签订合同
商品描述

About InVivoMAb anti-mouse PD-1 (CD279)

The 29F.1A12 monoclonal antibody reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments. Like the RMP1-14 and J43 antibodies the 29F.1A12 antibody has been shown to block the binding of PD-1 to its ligands in vivo.

InVivoMAb anti-mouse PD-1 (CD279) Specifications

Isotype

Rat IgG2a, κ

Recommended Isotype Control(s)InVivoMAb rat IgG2a isotype control, anti-trinitrophenol(BE0089)
Recommended InVivoPure Dilution BufferInVivoPure pH 7.0 Dilution Buffer(IP0070)
Immunogen

Recombinant PD-1-Ig fusion protein

Reported Applications
  • in vivo blocking of PD-1/PD-L signaling
  • in vitro PD-1 neutralization
  • Immunohistochemistry (frozen)
  • Immunofluorescence
  • Western blot
  • Flow cytometry
Endotoxin
  • <2EU/mg (<0.002EU/μg)
  • Determined by LAL gel clotting assay
Purity
  • >95%
  • Determined by SDS-PAGE
Formulation
  • PBS, pH 7.0
  • Contains no stabilizers or preservatives
Sterility

0.2 μM filtered

Production

Purified from tissue culture supernatant in an animal free facility

Purification

Protein G

Storage

The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.

RRID

AB_2687796

Molecular Weight

150 kDa

二、融合蛋白产品系列:Bio X Cell公司的重组蛋白是通过DNA技术生产,具有高纯度(SDS-PAGE测定达到95%以上)和低内毒素特性(LAL凝胶凝结试验小于2 EU /毫克),不含防腐剂或稳定剂,适用于生命科学研究及体内临床前治疗研究。在该系列产品总共包括5款优质融合蛋白,InVivoMAb重组CTLA-4-lg,InVivoMAb重组FLT-3L--lg,InVivoMAb重组小鼠Angiostatin-lg以及InVivoMAb重组小鼠Endostatin-lg。